Cargando…

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy

BACKGROUND: There is uncertainty about the appropriate use of primary prevention implantable cardioverter‐defibrillators (ICDs) among older patients with hypertrophic cardiomyopathy. METHODS AND RESULTS: Patients with hypertrophic cardiomyopathy who received a primary prevention ICD between 2010 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Sarah A., Kennedy, Kevin F., Friedman, Daniel J., Al‐Khatib, Sana M., Wang, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492935/
https://www.ncbi.nlm.nih.gov/pubmed/37586066
http://dx.doi.org/10.1161/JAHA.122.029293
_version_ 1785104364558352384
author Goldstein, Sarah A.
Kennedy, Kevin F.
Friedman, Daniel J.
Al‐Khatib, Sana M.
Wang, Andrew
author_facet Goldstein, Sarah A.
Kennedy, Kevin F.
Friedman, Daniel J.
Al‐Khatib, Sana M.
Wang, Andrew
author_sort Goldstein, Sarah A.
collection PubMed
description BACKGROUND: There is uncertainty about the appropriate use of primary prevention implantable cardioverter‐defibrillators (ICDs) among older patients with hypertrophic cardiomyopathy. METHODS AND RESULTS: Patients with hypertrophic cardiomyopathy who received a primary prevention ICD between 2010 and 2016 were identified using the National Cardiovascular Data Registry ICD Registry. Trends in ICD utilization and patient characteristics were assessed over time. Using linked Centers for Medicare and Medicaid Service claims data, Cox proportional hazard models assessed factors associated with mortality and postdischarge hospitalization for cardiac arrest/ventricular arrhythmia. Of 5571 patients with hypertrophic cardiomyopathy, 1511 (27.1%) were ≥65 years old. ICD utilization increased over time in all age groups. There were no changes in the prevalence of risk factors for sudden cardiac death over time. The variables most strongly associated with postdischarge mortality were older age (adjusted hazard ratio (aHR) 1.80 [95% CI, 1.47–2.21]), New York Heart Association class (III/IV versus I/II aHR 2.17 [95% CI, 1.57–2.98]), and left ventricular ejection fraction (left ventricular ejection fraction ≤35% versus >50% aHR 2.34 [95% CI, 1.58–3.48]; left ventricular ejection fraction 36%–50% versus >50% aHR 2.98 [95% CI, 2.02–4.40]), while history of nonsustained ventricular tachycardia (aHR 2.38 [95% CI, 1.62–3.51]) and New York Heart Association class (III/IV versus I/II aHR 1.84 [95% CI, 1.22–2.78]) were strongly associated with hospitalization for ventricular arrhythmia/cardiac arrest. CONCLUSIONS: Primary prevention ICD utilization in patients with hypertrophic cardiomyopathy increased over time, including among those ≥65 years old. Among older patients, the strongest risk factors for hospitalization for ventricular arrhythmia/cardiac arrest following ICD implantation were history of nonsustained ventricular tachycardia and New York Heart Association class.
format Online
Article
Text
id pubmed-10492935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104929352023-09-11 Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy Goldstein, Sarah A. Kennedy, Kevin F. Friedman, Daniel J. Al‐Khatib, Sana M. Wang, Andrew J Am Heart Assoc Original Research BACKGROUND: There is uncertainty about the appropriate use of primary prevention implantable cardioverter‐defibrillators (ICDs) among older patients with hypertrophic cardiomyopathy. METHODS AND RESULTS: Patients with hypertrophic cardiomyopathy who received a primary prevention ICD between 2010 and 2016 were identified using the National Cardiovascular Data Registry ICD Registry. Trends in ICD utilization and patient characteristics were assessed over time. Using linked Centers for Medicare and Medicaid Service claims data, Cox proportional hazard models assessed factors associated with mortality and postdischarge hospitalization for cardiac arrest/ventricular arrhythmia. Of 5571 patients with hypertrophic cardiomyopathy, 1511 (27.1%) were ≥65 years old. ICD utilization increased over time in all age groups. There were no changes in the prevalence of risk factors for sudden cardiac death over time. The variables most strongly associated with postdischarge mortality were older age (adjusted hazard ratio (aHR) 1.80 [95% CI, 1.47–2.21]), New York Heart Association class (III/IV versus I/II aHR 2.17 [95% CI, 1.57–2.98]), and left ventricular ejection fraction (left ventricular ejection fraction ≤35% versus >50% aHR 2.34 [95% CI, 1.58–3.48]; left ventricular ejection fraction 36%–50% versus >50% aHR 2.98 [95% CI, 2.02–4.40]), while history of nonsustained ventricular tachycardia (aHR 2.38 [95% CI, 1.62–3.51]) and New York Heart Association class (III/IV versus I/II aHR 1.84 [95% CI, 1.22–2.78]) were strongly associated with hospitalization for ventricular arrhythmia/cardiac arrest. CONCLUSIONS: Primary prevention ICD utilization in patients with hypertrophic cardiomyopathy increased over time, including among those ≥65 years old. Among older patients, the strongest risk factors for hospitalization for ventricular arrhythmia/cardiac arrest following ICD implantation were history of nonsustained ventricular tachycardia and New York Heart Association class. John Wiley and Sons Inc. 2023-08-10 /pmc/articles/PMC10492935/ /pubmed/37586066 http://dx.doi.org/10.1161/JAHA.122.029293 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Goldstein, Sarah A.
Kennedy, Kevin F.
Friedman, Daniel J.
Al‐Khatib, Sana M.
Wang, Andrew
Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title_full Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title_fullStr Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title_full_unstemmed Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title_short Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
title_sort utilization and outcomes of primary prevention implantable cardioverter‐defibrillators in patients with hypertrophic cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492935/
https://www.ncbi.nlm.nih.gov/pubmed/37586066
http://dx.doi.org/10.1161/JAHA.122.029293
work_keys_str_mv AT goldsteinsaraha utilizationandoutcomesofprimarypreventionimplantablecardioverterdefibrillatorsinpatientswithhypertrophiccardiomyopathy
AT kennedykevinf utilizationandoutcomesofprimarypreventionimplantablecardioverterdefibrillatorsinpatientswithhypertrophiccardiomyopathy
AT friedmandanielj utilizationandoutcomesofprimarypreventionimplantablecardioverterdefibrillatorsinpatientswithhypertrophiccardiomyopathy
AT alkhatibsanam utilizationandoutcomesofprimarypreventionimplantablecardioverterdefibrillatorsinpatientswithhypertrophiccardiomyopathy
AT wangandrew utilizationandoutcomesofprimarypreventionimplantablecardioverterdefibrillatorsinpatientswithhypertrophiccardiomyopathy